Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Study Phase : Phase I
Sponsor : Fortress Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.
Brand Name : Urece
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 29, 2023
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase I
Sponsor : Fortress Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?